• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Breast Cancer Drug Discoveries: What the Future Holds Product Image

Breast Cancer Drug Discoveries: What the Future Holds

  • ID: 679630
  • August 2011
  • 382 Pages
  • Espicom Business Intelligence Ltd

In 2010, almost 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are required to increase survival and delay disease progression.

Unique breast cancer market share, sales forecasts by launched and Phase III products to 2017

A comprehensive and critical examination and scoring of 72 major breast cancer treatments

Comprehensive market assessment of therapeutic approaches, company share, portfolios and prospects

Breast Cancer Therapy Sales Forecast 2010 - 2017

'What's the story behind this chart?'

The changing competitive landscape

By 2017, Espicom forecasts a modest increase in the number of players in the market-place compared to 2010, with Roche, and GlaxoSmithKline to a lesser extent, triumphing with targeted therapies directed against the specific subset of BC patients with HER2-positive disease. AstraZeneca, Novartis and Pfizer will face widespread generic competition for their hormonal therapies, leading to a loss of market share. Similarly, Sanofi and Eli Lilly will face declining sales for their chemotherapies.

The market in 2010...

In recent READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos